Aspira Women’s Health (AWH) to Release Earnings on Thursday

Aspira Women’s Health (NASDAQ:AWH) is scheduled to release its earnings data after the market closes on Thursday, March 28th. Analysts expect Aspira Women’s Health to post earnings of ($0.39) per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

Aspira Women’s Health Stock Down 1.4 %

NASDAQ AWH opened at $3.51 on Wednesday. The company has a market capitalization of $36.29 million, a PE ratio of -0.29 and a beta of 1.66. Aspira Women’s Health has a 12-month low of $2.31 and a 12-month high of $6.75. The firm’s 50 day moving average is $4.32 and its 200-day moving average is $4.32.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. increased its position in shares of Aspira Women’s Health by 7.2% in the fourth quarter. Vanguard Group Inc. now owns 196,007 shares of the company’s stock worth $800,000 after purchasing an additional 13,162 shares during the period. Northern Trust Corp boosted its position in shares of Aspira Women’s Health by 227.7% during the 4th quarter. Northern Trust Corp now owns 36,049 shares of the company’s stock worth $147,000 after acquiring an additional 25,047 shares in the last quarter. B. Riley Wealth Advisors Inc. increased its stake in Aspira Women’s Health by 19.6% in the first quarter. B. Riley Wealth Advisors Inc. now owns 792,728 shares of the company’s stock valued at $290,000 after acquiring an additional 129,662 shares during the last quarter. Citadel Advisors LLC raised its position in Aspira Women’s Health by 66.2% during the second quarter. Citadel Advisors LLC now owns 252,841 shares of the company’s stock valued at $149,000 after purchasing an additional 100,727 shares in the last quarter. Finally, Millennium Management LLC lifted its stake in Aspira Women’s Health by 1,074.4% during the second quarter. Millennium Management LLC now owns 760,611 shares of the company’s stock worth $447,000 after purchasing an additional 695,844 shares during the last quarter. 12.19% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, StockNews.com downgraded Aspira Women’s Health from a “hold” rating to a “sell” rating in a research note on Friday, March 22nd.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company's products include Ova1, a blood test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker reflex test; and Ova1Plus, a reflex offering.